Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

656
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
656
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

1.9K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
1.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fixed-dose telmisartan/hydrochlorothiazide in comparison with losartan/hydrochlorothiazide in decreasing serum hepatocyte growth factor and improving endothelial dysfunction in hypertensive patients.

International heart journal·2010
Same author

[Relationship between Mutations of the Epidermal Growth Factor Receptor Gene and Drug-Resistance to Gefitinib in Human Lung Cancer in vitro.].

Zhongguo fei ai za zhi = Chinese journal of lung cancer·2010
Same author

Pupal diapause of Helicoverpa armigera (Hübner) (Lepidoptera: Noctuidae) mediated by larval host plants: pupal weight is important.

Journal of insect physiology·2010
Same author

Clinical application and evaluation of anti-TNF-alpha agents for the treatment of rheumatoid arthritis.

Acta pharmacologica Sinica·2010
Same author

Regulatory effect of melatonin on cytokine disturbances in the pristane-induced lupus mice.

Mediators of inflammation·2010
Same author

Management of maxillary sinus inverted papilloma via transnasal endoscopic anterior and medial maxillectomy.

ORL; journal for oto-rhino-laryngology and its related specialties·2010
Same journal

Safety, efficacy, and pharmacokinetics of eratrectinib (VC004) in solid tumors with NTRK fusions: phase 1 results from a phase 1/2 study.

Experimental hematology & oncology·2026
Same journal

MAGEC2 promotes tumorigenesis in multiple myeloma through USP16-mediated deubiquitination and stabilization of c-Myc.

Experimental hematology & oncology·2026
Same journal

Biology-informed risk stratification of glioblastoma by integrating MRI-based intratumoral heterogeneity with clinical features: a multicenter validation study.

Experimental hematology & oncology·2026
Same journal

Real-world evidence on infection risk in multiple myeloma treated with BiTEs and CAR-T cells: a meta-analysis.

Experimental hematology & oncology·2026
Same journal

Breathing new life into T-cell receptor-engineered T-cell therapy in solid tumors: enhancing strategies to expand the universality of precision therapy.

Experimental hematology & oncology·2026
Same journal

Clinical research progress of menin inhibitors for acute myeloid leukemia: latest updates from the 2025 ASH Annual Meeting.

Experimental hematology & oncology·2026
See all related articles

Related Experiment Video

Updated: Sep 7, 2025

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
06:10

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

427

TCR engineered T cells for solid tumor immunotherapy.

Yikai Zhang1,2,3,4, Zhipeng Liu1,2, Wei Wei5,6

  • 1Guangzhou Municipality Tianhe Nuoya Bio-engineering Co. Ltd, Guangzhou, 510663, China.

Experimental Hematology & Oncology
|June 20, 2022
PubMed
Summary
This summary is machine-generated.

T cell receptor (TCR)-engineered T cells show promise for solid tumor immunotherapy, offering advantages over chimeric antigen receptor (CAR)-T cells. Current advances and potential benefits are summarized.

Keywords:
Cellular immunotherapySolid tumorsT cell receptorTCR-T cells

More Related Videos

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

789
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.5K

Related Experiment Videos

Last Updated: Sep 7, 2025

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
06:10

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

427
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

789
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.5K

Area of Science:

  • Immunology
  • Oncology
  • Biotechnology

Background:

  • T cell immunotherapy is a key strategy in cancer treatment.
  • Chimeric antigen receptor (CAR)-T cell therapy is effective for hematological cancers.
  • T cell receptor (TCR)-engineered T cells can target intracellular and cell surface antigens.

Purpose of the Study:

  • To review current advancements in TCR-engineered T cell therapy.
  • To highlight the potential advantages of TCR-T cells for solid tumor immunotherapy.

Main Methods:

  • Literature review of current TCR-T cell research and clinical trials.
  • Analysis of TCR-T cell mechanisms and antigen recognition capabilities.
  • Comparison of TCR-T cells with CAR-T cells for solid tumor applications.

Main Results:

  • TCR-T cells offer broader antigen targeting compared to CAR-T cells.
  • Clinical trials indicate potential efficacy of TCR-T cells in solid tumors.
  • TCR-T cell technology is advancing for improved solid tumor treatment.

Conclusions:

  • TCR-engineered T cells represent a promising frontier in solid tumor immunotherapy.
  • Further research and clinical trials are warranted to optimize TCR-T cell therapy for solid tumors.